Rare Therapeutics
Rare Therapeutics (RareTx) is a clinical-stage gene therapy company, spun out of GEMMABio in October 2025, developing treatments for ultra-rare lysosomal storage diseases (GM1, Krabbe, MLD) for delivery through an international coalition of public-private partnerships.
- Company typePrivate
- Founded2025
- HeadquartersPhiladelphia, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rare Therapeutics does
Rare Therapeutics, Inc. (RareTx) is a clinical-stage gene therapy company that launched on October 7, 2025 as an affiliate of GEMMABio, headquartered at 125 S. 31st St., Philadelphia, PA. The company is built on Dr. Jim Wilson's 40-year career pioneering the development and delivery of gene therapies for rare diseases, and focuses exclusively on ultra-rare lysosomal storage diseases — specifically GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD) — targeting patient populations with prevalence under 1:100,000 where no approved treatments currently exist. Its technology foundation is a next-generation gene delivery and manufacturing platform developed through decades of research investment, intended to enable platform-based development across multiple ultra-orphan indications rather than single-product economics.
Raretx has not yet generated revenue and remains pre-commercial, with 1–10 employees at formation and no disclosed external funding rounds or institutional investors. Its intended go-to-market is structurally unconventional for gene therapy: rather than premium pricing through standard commercial channels, the company plans to distribute its therapies through an international coalition of public-private partnerships and regional centers of excellence designed to ensure affordable worldwide access. The strategic premise is that ultra-rare diseases are too small to justify traditional investment models, and that novel funding architectures combined with platform technology can produce a sustainable pipeline of treatments. Near-term strategic signals include broad coverage in tier-one biotech media (Fierce Biotech, Endpoints News, BioBuzz) and selection as a Philadelphia Business Journal 'Startup to Watch' for 2026, but financial scale, pipeline progression timelines, and partnership economics remain undisclosed.
Rare Therapeutics firmographics
Firmographics- Name
- Rare Therapeutics
- Legal name
- Rare Therapeutics, Inc.
- Website
- https://raretx.us
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Rare Therapeutics (RareTx) is a clinical-stage gene therapy company, spun out of GEMMABio in October 2025, developing treatments for ultra-rare lysosomal storage diseases (GM1, Krabbe, MLD) for delivery through an international coalition of public-private partnerships.
- Ownership category
- akta.pro rank
Rare Therapeutics industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industries
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where Rare Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Rare Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Gene therapy product sales: Revenue derived from developing and commercializing gene therapy treatments for ultra-rare lysosomal storage diseases including GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy. The company aims to enhance quality and affordability of gene therapy products through international public-private partnerships.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Rare Therapeutics product offering
Product offeringCore offering
Rare Therapeutics (RareTx) is a clinical-stage biotechnology company developing gene therapies for ultra-rare lysosomal storage diseases, specifically GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD). The company leverages next-generation gene delivery and manufacturing technologies built on Dr. Jim Wilson's 40-year pioneering research, and distributes treatments through an international coalition of public-private partnerships to enable affordable global access.
Product overview
RareTx is a clinical-stage therapeutics company with a single unified gene therapy product pipeline targeting three lysosomal storage diseases: GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD). The company operates as an affiliate of GEMMABio and is building on Dr. Jim Wilson's pioneering work in gene therapy. Treatments are delivered through an international coalition of public-private partnerships to enable affordable access to ultra-orphan disease patients globally.
Differentiator
Problem solved
Functional benefit
Products and services
- Gene Therapy Pipeline (GM1, Krabbe disease, MLD) Clinical-stage gene therapy portfolio targeting ultra-rare lysosomal storage diseases (GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy), developed using next-generation gene delivery and manufacturing technologies and delivered through an international coalition of public-private partnerships to ensure affordable global access for patients with these conditions.
Quantifiable outcome
- Only 5% of rare diseases currently have available treatments, creating significant unmet medical need
- +2 more outcomes
Companies that use Rare Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Rare Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Rare Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GEMMABiocoreRareTx is an affiliate of GEMMABio, which launched the company on October 7, 2025. GEMMABio provides strategic support and backing to Rare Therapeutics, enabling the company to enhance quality and affordability of gene therapy products while leading to greater access and a sustainable pipeline of treatments for ultra-rare diseases.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Rare Therapeutics competitors and assessment
Company assessmentEmerging players
- REGENXBIO: REGENXBIO develops AAV gene therapy platforms and treatments for rare diseases, including partnerships across multiple rare disease programs; comparable as a gene delivery technology provider adjacent to RareTx's AAV modality.
Direct peers
- Passage Bio: Passage Bio is a clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases, directly comparable to RareTx in modality (AAV gene therapy), disease area (rare neurological), and development stage.
- Prevail Therapeutics (Eli Lilly): Prevail Therapeutics develops AAV-based gene therapies for neurodegenerative diseases, including approaches for lysosomal storage and CNS disorders that overlap directly with RareTx's GM1, Krabbe, and MLD targets.
- Solid Biosciences: Solid Biosciences is a clinical-stage gene therapy company focused on rare neuromuscular and CNS diseases, comparable to RareTx in clinical-stage AAV gene therapy development for underserved rare populations.
- Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage gene therapy company targeting rare diseases including CNS and cardiac indications, overlapping with RareTx's rare disease AAV gene therapy positioning and platform approach.
- Taysha Gene Therapies: Taysha Gene Therapies is a clinical-stage gene therapy company developing AAV-based therapies for ultra-rare CNS disorders, with a pipeline model closely mirroring RareTx's ultra-orphan CNS-focused strategy.
Broad incumbents
- Spark Therapeutics (Roche): Spark Therapeutics pioneered approved AAV gene therapies (e.g., Luxturna) and operates as Roche's gene therapy unit, representing a broader incumbent in rare disease AAV gene therapy development and commercialization.
- bluebird bio: bluebird bio is a gene therapy company developing treatments for severe genetic diseases including rare neurological and metabolic conditions, comparable to RareTx's focus on ultra-rare genetic disorders via advanced therapy modalities.
- BioMarin Pharmaceutical: BioMarin is a global rare disease biopharmaceutical company with approved enzyme replacement and gene therapies for conditions including certain lysosomal storage diseases, operating as a broad incumbent addressing similar patient populations.
- Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease biopharmaceutical company with multiple approved therapies and gene therapy programs, including for lysosomal storage diseases - a broader incumbent competing across the same rare disease category as RareTx.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Rare Therapeutics social profiles
Digital presenceRare Therapeutics compliance and trust
Trust signalCompliance1 record
Rare Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rare Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Rare Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rare Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rare Therapeutics
What does Rare Therapeutics do?
Rare Therapeutics (RareTx) is a clinical-stage biotechnology company developing gene therapies for ultra-rare lysosomal storage diseases, specifically GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD). The company leverages next-generation gene delivery and manufacturing technologies built on Dr. Jim Wilson's 40-year pioneering research, and distributes treatments through an international coalition of public-private partnerships to enable affordable global access.
Is Rare Therapeutics a public or private company?
Rare Therapeutics is a private company. It is classified as corporate owned and is currently operating.
When was Rare Therapeutics founded?
Rare Therapeutics was founded in 2025. It employs 1 to 10 people.
Where is Rare Therapeutics based?
Rare Therapeutics is headquartered in Philadelphia, United States, in the North America region.
How does Rare Therapeutics make money?
One revenue line is on record: gene therapy product sales.
Who are Rare Therapeutics's main competitors?
REGENXBIO is listed as an emerging player. Direct peers are Passage Bio, Prevail Therapeutics (Eli Lilly), Solid Biosciences, Lexeo Therapeutics and Taysha Gene Therapies. Broad incumbents are Spark Therapeutics (Roche), bluebird bio, BioMarin Pharmaceutical and Ultragenyx Pharmaceutical.
Does Rare Therapeutics have an API?
No public API is recorded for Rare Therapeutics.
What industry is Rare Therapeutics in?
Rare Therapeutics's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.